FBFlorien Willemijn Boele

Florien Willemijn Boele

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Florien Willemijn Boele has a total of 353 co-authors. Here are the top co-authors by number of shared publications:

  • Martin Klein

    Department of Medical Psychology, Amsterdam UMC, Vrije Universiteit Amsterdam , Amsterdam , the Netherlands

    14 shared publications
  • Karin Piil

    Department of Oncology, Centre for Cancer and Organ Diseases, Copenhagen University Hospital, Rigshospitalet , Copenhagen

    11 shared publications
  • Jaap C. Reijneveld

    Department of Neurology, Amsterdam UMC, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands

    8 shared publications
  • Jan J. Heimans

    Department of Neurology, Amsterdam UMC, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands

    7 shared publications
  • Emma Nicklin

    Leeds Institute of Medical Research at St James’ Hospital, University of Leeds, Leeds, UK

    6 shared publications
  • Linda Dirven

    Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands

    6 shared publications

Latest Publications

  • Open Access

    Breaking barriers and shaping futures: A sequential multi-methods exploration of career pathways for nurses and allied health professionals

    by Aoife Williamson, Lena Rosenlund, Karin Piil, Sara Nordentoft, Sara Melhuish, Isabelle Rydén, Marike Donders-Kamphuis, Sharon Fernandez, Helle Sorenson von Essen, Georgia Halkett, et al.

    Background: Nurses and Allied Health Professionals (AHPs) are essential to neuro-oncology multidisciplinary teams (MDTs) in delivering holistic, person-centered care. Despite their central role, the career development landscape for neuro‑oncology nurses and AHPs remains fragmented, with limited opportunities for structured progression, advanced training, or protected time for professional growth. We aimed to identify key barriers to professional development and generate practical, actionable strategies to build capacity. Methods: We conducted qualitative focus groups with neuro-oncology nurses and AHPs to generate barriers and solutions to career development and progression, followed by a quantitative survey to rank barriers and solutions for priority and feasibility. A rapid qualitative synthesis of focus group findings informed the survey questions, which were analyzed descriptively. Based upon expert consensus, a set of practical and actionable solutions was proposed. Results: Ten nurses and AHPs took part, representing Sweden, Denmark, the United Kingdom, and the Netherlands, and included junior- and senior-level roles. Across 4 topics (variability in education opportunities, the MDT environment, practical barriers, and building the next generation), a total of 23 barriers and 32 solutions were generated in focus groups and then ranked in the survey exercise. Ten action points were generated to guide the strategy of the EANO Nurse and Allied Health Professions Committee. Conclusions: The collective insights of nurses and AHPs from different countries, at different career stages, helped shape a robust strategic action plan. Grounded in real‑world experiences and shared challenges, our results offer a practical roadmap for strengthening capacity and supporting career development.

  • Open Access

    Core outcome set for quality of life of family caregivers of adults with epilepsy: A Delphi consensus study

    by Florien Boele, Famke Visser, Maeike Zijlmans, Maaike Schuur, Stephanie Peters, Francis Saridin, Lydia van Den Berg, Aysun Altinbas, Rolf Fronczek, Roland Thijs, et al.

    Objective: Epilepsy significantly affects daily functioning and health‐related quality of life (HRQOL) of those living with the condition. Less is known about HRQOL of family caregivers of adults with epilepsy, yet the functioning of patients and caregivers is interlinked, and caregivers' unmet support needs are high. A consensus‐based core outcome set for caregivers' HRQOL can guide more structured caregiver assessments and aid timely intervention. Methods: A three‐round Delphi study was conducted to determine outcomes most important for family caregivers' HRQOL. Three stakeholder groups were recruited: experts‐by‐experience (caregivers/adults with epilepsy), healthcare professionals, and researchers. Across two survey rounds, participants rated outcomes for relevance, feasibility, and amenability to change. A predefined consensus threshold (≥80% agreement on relevance) guided outcome selection. In round three, participants prioritized three relevant outcomes per HRQOL domain. The resulting preliminary core outcome set was reviewed by a second stakeholder panel for scope, overlap, and feasibility before finalizing. Results: Thirty‐four experts‐by‐experience, healthcare professionals, and researchers from 10 countries participated. In rounds 1 ( N = 34) and 2 ( N = 32), 41 outcomes reached the ≥80% relevance threshold and were retained. In round 3 ( N = 30), participants prioritized 18 outcomes. After review by the second panel ( N = 25), the final core outcome set includes caregivers' physical functioning (general health, sleep, fatigue), emotional functioning (emotional (in)stability, seizure worry, overwhelm, resilience), social functioning (personal relationships, family relationships, social stigma), spiritual/religious functioning (hope, purpose/meaning), tasks/responsibilities (understanding diagnosis and treatment, coping with behavior changes), and self‐care, respite, and financial security. We recommend outcome measures prioritized for good psychometric properties, language availability, and low burden of administration to facilitate caregiver assessments. Significance: This international Delphi consensus study established 18 core outcomes for HRQOL of caregivers of adults with epilepsy. Structured assessment of the core outcome set using validated tools can support timely detection of and intervention to alleviate HRQOL issues in caregivers.

  • Interventions addressing informational needs of adults with primary malignant brain tumors: A systematic review

    by Maria Camilla Mathiasen, Florien Boele, Georgia K B Halkett, Anders Overby Sjøstrøm, Dorte Schou Nørøxe, Helle Pappot, Karin Piil

    Background: Patients with primary malignant brain tumors (PMBT) and their caregivers face informational challenges due to cognitive impairment, emotional distress, and complex treatment trajectories. Although informational interventions have been developed, effectiveness and scope remain unclear. This systematic review aimed to synthesize evidence on interventions addressing informational needs in this population. Methods: Five databases (MEDLINE, Embase, Cochrane Library, CINAHL, PsycINFO) were searched for studies published between 2015 and 2025. Studies included adult patients with PMBT and evaluated interventions targeting informational needs or understanding. All study designs were included. Data were extracted and synthesized using a narrative approach due to heterogeneity. Methodological quality was assessed using the Mixed-Methods Appraisal Tool. Results: Thirty studies were included, comprising qualitative, quantitative, and mixed-methods designs. Interventions were heterogeneous and included psychoeducational, psychological, communication-support, family-based, and digital approaches. Many interventions improved outcomes such as psychological distress, disease understanding, self-management, and quality of life. Communication-support tools enhanced recall and patient involvement, while family-based interventions improved shared understanding. No single intervention was designed to comprehensively address informational needs across the disease trajectory, reflecting the complexity of care needs in PMBT. Information-related outcomes were inconsistently defined and rarely primary endpoints. Methodological limitations included sample sizes, variable adherence, and limited use of validated measures. Conclusions: Informational needs in PMBT care are complex, dynamic, and insufficiently addressed by existing interventions. Findings support the need for flexible, tailored, and iterative informational strategies rather than single standardized approaches. Future research should prioritize standardized outcome measures and develop adaptive interventions aligned with evolving patient and caregiver needs.

  • Open Access

    “It’s a club nobody wanted to join, but we’re there”: Focus groups on end-of-life care experiences and long-term outcomes of bereaved neuro-oncology caregivers

    by Shaista Meer, Rosanna Miller, Peter Buckle, Louise Murray, Catherine Lewis-Smith, Lucy Ziegler, Karin Piil, Florien Boele

    Background: The disease burden of malignant brain tumours poses significant challenges to both patients and their family caregivers. Even years post-bereavement, neuro-oncology caregivers can suffer serious and long-lasting adverse outcomes. A previous quantitative survey (reported separately) highlighted significant challenges experienced by bereaved neuro-oncology caregivers. This current work explored these issues further through focus groups. Objective: To identify opportunities to enhance support, we investigated caregiver experiences during the patient’s end-of-life phase, the dying process, and post-bereavement outcomes. Design: Focus groups as a component of a sequential mixed-methods study designed together with bereaved caregivers. Methods: We performed online focus groups covering the end-of-life phase, the period surrounding the patient’s death, and their post-bereavement outcomes. Sampled from survey respondents, caregivers who were ≥6 months post-bereavement were invited to take part in online focus groups. Following audio transcription, data were analysed using reflexive thematic analysis. Results: In three groups, 7 female (64%) and 4 male (36%) caregivers (55% partners of patients) of deceased patients diagnosed with glioblastoma were interviewed. Themes covered 1) care experiences in the end-of-life phase (covering communication, information, support needs, and balancing family dynamics), 2) caregiver experiences surrounding patient death, and 3) immediate and longer-term post-bereavement outcomes (covering complex and conflicting emotional responses, expectations and strategies to cope with grief, and the value of formal and informal support). Conclusions: Findings highlight ongoing significant and unmet emotional support needs of bereaved neuro-oncology caregivers. Caregivers want and deserve to be proactively offered adequate and timely support which could limit the long-lasting adverse impact of providing care.

  • Open Access

    Clinical Oncologist and NHS Commissioner Perspectives on Reirradiation for Recurrent Cancer

    by F. Slevin, S. Kendal, A.L. Appelt, M. Aznar, R. Benson, P. Bhatnagar, C. Chan, S. Chowdhury, A. Crellin, A. Duffton, et al.

  • Open Access

    Patient Perspectives on Reirradiation for Recurrent Cancer, to Inform Future Clinical Trial Design

    by F. Slevin, S. Kendal, A.L. Appelt, M. Aznar, C. Chan, A. Duffton, C. Faivre-Finn, M. Harrison, S. Harrow, A.M. Henry, et al.

  • Open Access

    Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation

    by Florien W Boele, Sé M Frances, Amélie Darlix, Francois Ducray, Stéphanie Cartalat, Estelle Guerdoux, Emeline Tabouret, Michael C Burger, Isabelle Rydén, Annika Malmstrom, et al.

    Background: Patients with oligodendroglioma have a relatively favorable prognosis. The long-term impacts of the tumor itself and its treatment on health-related quality of life (HRQOL) and cognition remain largely unclear. We investigated associations between treatment and functioning of survivors of oligodendroglioma. Methods: In this cross-sectional observational study, patients with oligodendroglioma, isocitrate dehydrogenase-mutant and 1p/19q-codeleted, diagnosed ≥ 5 years ago, were recruited. Patients completed patient-reported outcome measures (EORTC QLQ-C30; BN20; MOS Cognitive Complaints Scale) and cognitive tests (HVLT-R, TMT, COWAT). Associations between HRQOL and cognition outcomes, and clinical variables (time since diagnosis; age at diagnosis; progression; tumor location; treatments delivered; time since treatment; current medication) were explored with regression analyses. Results: In total, 237 patients M = 9.9 years postdiagnosis (SD = 4.2, range 5.0-25.8) took part from 33 sites across 9 countries. Clinically relevant levels of impairment were noted in >40% of patients on EORTC QLQ-C30 scales for cognitive functioning (56.1%), emotional functioning (49.8%), fatigue (45.1%), and physical functioning (40.5%). In individuals, cognitive impairment ranged from 17.7% for processing speed to 46.0% for episodic verbal memory (delayed recall). Among other clinical factors such as current use of antiseizure medication or antidepressants, age, disease progression, time since diagnosis and time since treatment, and radiotherapy treatment (ever received) was linked to HRQOL and cognitive functioning outcomes (posthoc analyses for cumulative radiotherapy dose: not significant). Conclusions: In oligodendroglioma survivors, HRQOL and cognitive impairment are prevalent even years into follow-up. Supportive care and rehabilitation should be prioritized to mitigate these challenges and improve daily functioning. Trial registration: NCT04708548


  • Group-based interventions for caregivers to patients diagnosed with a brain tumor: A systematic review

    by Sara Nordentoft, Florien Boele, Rikke Guldager, Anders Larsen, Caroline Hertler, Paula Sherwood, Helle Pappot, Tiit Mathiesen, Karin Piil

    Background: Individuals diagnosed with a primary brain tumor often depend on practical assistance and emotional support from family and social network. Supportive care interventions are therefore of importance to informal caregivers. The aim of this review was to identify and explore available evidence of outcomes of supportive group interventions for caregivers to patients diagnosed with a primary brain tumor. Methods: A systematic review was conducted following the PRISMA guidelines. Six databases: PubMed, Embase, Web of Science, Emcare, Cochrane Library, and PsycINFO were searched for peer-reviewed publications. Quality of included publications was assessed by the Mixed-Methods Appraisal Tool and data synthesis followed Guidance on the Conduct of Narrative Synthesis in Systematic Reviews. Results: Five eligible publications were identified, published between 2007 and 2021, originating from Australia, Austria, Canada, Denmark, and Germany. Supportive group interventions for caregivers to patients diagnosed with a primary brain tumor were considered feasible, with outcomes evaluated positively in 5 publications. The group interaction within a supportive intervention created a trusted environment for caregivers to share their experiences. Group interactions represented an essential source of support and information to manage the caregiver role. Shared acknowledgment of their new role boosted caregivers’ confidence in their abilities to deliver care. Conclusion: Interventions seeking to facilitate interaction between caregivers may provide an extra supportive resource for the caregivers. Nevertheless, further research is necessary to ascertain the optimal setting, content, and timing for providing caregivers a supportive group intervention.


  • Open Access

    End-of-life care experiences and long-term outcomes of bereaved neuro-oncology caregivers: A cross-sectional survey

    by Shaista Meer, Peter Buckle, Rosanna Miller, Louise Murray, Lucy Ziegler, Karin Piil, Florien Boele

    Background: The last three months of life (end-of-life phase) are profoundly challenging for patients with brain tumours and their family caregivers. Post-bereavement outcomes are largely unknown. Aim: To better understand long-term outcomes of a brain tumour diagnosis on families, we aimed to describe caregiver experiences during the end-of-life phase and beyond. Design: In this sequential mixed-methods study designed together with bereaved caregivers, we used an online survey. This comprised end-of-life experiences, and post-bereavement outcomes (family functioning: Family APGAR; resilience: CD-RISC-10; mood: HADS; prolonged grief: PG-13-R; post-traumatic stress: TSQ). Setting/Participants: Caregivers of patients with brain tumours who were bereaved ⩾6 months ago were invited through social media and charities. Results: 105 bereaved neuro-oncology caregivers participated. The end-of-life phase was marked by high symptom burden and disruption to family life, compounded by often unsatisfactory information provision and support. Forty-three percent did not describe the patient’s death as dignified. Most caregivers were not well-supported post-bereavement, and current functioning was impacted by notable rates of prolonged grief disorder (64%), post-traumatic stress disorder (42%), depression (35%), anxiety (61%), disruption to family life (53%) and low levels of resilience. Multivariable regressions found better resilience and family functioning to be protective factors for both post-traumatic stress disorder and prolonged grief disorder symptoms, with a dignified death additionally linked to caregivers’ prolonged grief scores, explaining 23.8% and 51.0% of variance, respectively. Conclusions: Bereaved neuro-oncology caregivers have high rates of adverse mental health outcomes, highlighting a pressing need for improvements in palliative, end-of-life and post-bereavement services.


  • Response Assessment in Neuro-Oncology (RANO) 2009–2025: Broad scope and implementation—A progress report

    by Martin J van Den Bent, Michael A Vogelbaum, Tim Cloughesy, Norbert Galldiks, Nathalie L Albert, Joerg-Christian Tonn, Edward Avila, Jason Fangusaro, David Mirsky, Arjun Sahgal, et al.

    Since its first activities in 2008 and 2009, the Response Assessment in NeuroOncology (RANO) group has given guidance on response assessment, trial design, and trial procedures to improve and standardize the way clinical trials in neurooncological studies are performed. To achieve its objectives, a variety of working groups have been initiated that cover many aspects of clinical trial design and outcome assessment in patients with tumors affecting the Central Nervous System. The RANO working groups are built on expertise without a formal structure, which makes rapid responses to new developments possible. RANO is aiming at evidence-based guidelines and recommendations, but in the absence of evidence will provide consensus-based guidance achieved by inviting recognized international experts. In its 15 years of existence, more than 60 RANO papers have been published mostly in high-ranking journals, and its recommendations have been accepted by regulators and industry as guiding principles. RANO organizes two meetings per year, one in conjunction with the annual American Society for Clinical Oncology (ASCO) meeting, and one during the annual Society for Neuro-Oncology meeting. These meetings are open, as are the working groups of RANO. New initiatives are welcomed.